Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features

American Journal of Surgical Pathology

Volumn 40, Issue 3, 2016, Pages 335-341

  Ondrejka, Sarah L ^a   Grzywacz, Bartosz ^a   Bodo, Juraj ^a   Makishima, Hideki ^a   Polprasert, Chantana ^a   Said, Jonathan W ^b   Przychodzen, Bartlomiej ^a   Maciejewski, Jaroslaw P ^a   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Angioimmunoblastic T cell lymphoma; RHOA G17V; T cell non Hodgkin lymphoma

Indexed keywords

RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; ENZYMOLOGY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOBLASTIC LYMPHADENOPATHY; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; SPLENOMEGALY; T CELL LYMPHOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL; MALE; MICROVESSELS; MIDDLE AGED; MUTATION; PHENOTYPE; RHOA GTP-BINDING PROTEIN; SPLENOMEGALY;

EID: 84959156656     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000555     Document Type: Article

References (31)

1. Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/Tcell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-4130.
2. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240-246.
3. Dogan A, Gaulard P, Jaffe E, et al. Angioimmunoblastic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC; 2008:309-310, 311.
4. Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood. 1992;79:1789-1795.
5. Zettl A, Lee SS, Rudiger T, et al. Epstein-barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117:368-379.
6. Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627-633.
7. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): A new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490-494.
8. Marafioti T, Paterson JC, Ballabio E, et al. The inducible T-cell costimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica. 2010;95:432-439.
9. Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol. 2007;14:348-353.
10. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952-4963.
11. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007;67:10703-10710.
12. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011; 20:25-38.
13. Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014; 123:1293-1296.
14. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366: 95-96.
15. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119: 1901-1903.
16. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014; 46:171-175.
17. Palomero T, Couronne L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46:166-170.
18. Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:371-375.
19. Hsi ED, Said J, Macon WR, et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol. 2014;38:768-775.
20. Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: Clinical correlation and insights into natural history and disease progression. Am J Surg Pathol. 2007;31:1077-1088.
21. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
22. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117:e198-e206.
23. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478:64-69.
24. Rougerie P, Delon J. Rho GTPases: masters of T lymphocyte migration and activation. Immunol Lett. 2012;142:1-13.
25. Tybulewicz VL, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol. 2009;9:630-644.
26. Corre I, Gomez M, Vielkind S, et al. Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. J Exp Med. 2001;194:903-914.
27. Cools J. RHOA mutations in peripheral T cell lymphoma. Nat Genet. 2014;46:320-321.
28. Cleverley SC, Costello PS, Henning SW, et al. Loss of rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene. 2000;19:13-20.
29. Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010;24:3186-3195.
30. Konstantinou K, Yamamoto K, Ishibashi F, et al. Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol. 2009;144:696-704.
31. Lemonnier F, Couronne L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120: 1466-1469.